Seattle-area psychedelics startup CaaMTech raises $22M to advance to human testing
GeekWire
SEPTEMBER 10, 2021
CaaMTech , a Seattle-area startup developing new psychedelic agents, has raised $22 million in funding, the company announced this week. CaaMTech is developing a suite of tryptamines with the aim of finding mixes that “optimize desired effects while minimizing unwanted side-effects,” according to the company’s website.
Let's personalize your content